MA
PMCB icon

MCF Advisors’s PharmaCyte Biotech PMCB Stock Holding History

MCF Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Hold
1
– – ﹤0.01% 1337
2025
Q4 		$1 Buy
+1
New +$1 ﹤0.01% 1133

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MCF Advisors's PMCB Position: Q1 2026 in Review

MCF Advisors held its PharmaCyte Biotech (PMCB) position steady in Q1 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #1337.

MCF Advisors first reported a position in PMCB in Q4 2025 and has held it in 2 quarters since. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • MCF Advisors held 1 share of PharmaCyte Biotech worth $1 as of Q1 2026.
  • MCF Advisors left its PharmaCyte Biotech share count unchanged in Q1 2026.
  • PharmaCyte Biotech made up ﹤0.01% of MCF Advisors's portfolio in Q1 2026, its #1337 holding.
  • MCF Advisors first reported a position in PharmaCyte Biotech in Q4 2025 and has held it in 2 quarters since.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on MCF Advisors's 13F filing for Q1 2026, filed 11 May 2026.